Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche's Xofluza Reduces Flu Symptoms In Children

Executive Summary

The Swiss group's one-dose drug, seen as a future growth driver, is as effective as its off-patent blockbuster Tamiflu in treating children. 

You may also be interested in...



Roche Expects Better Xofluza Sales After New Indication

Flu treatment is newly approved for patients at higher risk of flu complications, and Roche is studying other patient groups that could help expand its potential market.      

UK's AMRC Licenses Shionogi Superbug Therapy

As it waits for a US FDA decision on its antibiotic cefiderocol, the Japanese company has handed over the rights to a Pseudomonas aeruginosa therapy that will go into the clinic next year.

Prophylaxis Results Set Stage For Expanded Japan Xofluza Use

Shionogi’s novel single-dose flu drug shows promise in first Phase III results in post-exposure prevention, paving the way for a Japanese filing in this setting and potentially expanding already healthy sales.

 

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC125489

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel